BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9086151)

  • 1. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M; Stites DP; Farhat S; Sisler JR; Moss B; Kong F; Moscicki AB; Palefsky JM
    J Infect Dis; 1997 Apr; 175(4):927-31. PubMed ID: 9086151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
    J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.
    Bontkes HJ; de Gruijl TD; van den Muysenberg AJ; Verheijen RH; Stukart MJ; Meijer CJ; Scheper RJ; Stacey SN; Duggan-Keen MF; Stern PL; Man S; Borysiewicz LK; Walboomers JM
    Int J Cancer; 2000 Oct; 88(1):92-8. PubMed ID: 10962445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
    Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
    Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
    Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
    Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
    J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
    Nimako M; Fiander AN; Wilkinson GW; Borysiewicz LK; Man S
    Cancer Res; 1997 Nov; 57(21):4855-61. PubMed ID: 9354449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
    Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses.
    Nakagawa M; Stites DP; Palefsky JM; Kneass Z; Moscicki AB
    Clin Diagn Lab Immunol; 1999 Jul; 6(4):494-8. PubMed ID: 10391849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia.
    Sathish N; Abraham P; Peedicayil A; Sridharan G; John S; Chandy G
    Mol Diagn; 2004; 8(1):57-64. PubMed ID: 15230643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serologic response in human papillomavirus-associated invasive cervical cancer.
    Viscidi RP; Sun Y; Tsuzaki B; Bosch FX; Muñoz N; Shah KV
    Int J Cancer; 1993 Nov; 55(5):780-4. PubMed ID: 8244575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.
    Ressing ME; van Driel WJ; Celis E; Sette A; Brandt MP; Hartman M; Anholts JD; Schreuder GM; ter Harmsel WB; Fleuren GJ; Trimbos BJ; Kast WM; Melief CJ
    Cancer Res; 1996 Feb; 56(3):582-8. PubMed ID: 8564975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of human papillomavirus 16 E6/E7 variants in cervical cancer and intraepithelial neoplasia in Chinese women.
    Ding T; Wang X; Ye F; Cheng X; Lu W; Xie X
    Int J Gynecol Cancer; 2010 Nov; 20(8):1391-8. PubMed ID: 21051983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN).
    Mathur SP; Mathur RS; Rust PF; Young RC
    Am J Reprod Immunol; 2001 Oct; 46(4):280-7. PubMed ID: 11642677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.